Montana enacted legislation this week that creates a fast-track pathway for experimental drug companies to sell treatments directly to consumers. The process bypasses traditional FDA approval.

Biotech firms can now submit drugs that have completed only preliminary testing, sometimes involving as few as 10 healthy volunteers, to a state review board. The $12,500 application fee grants access to a streamlined approval process. Once the state board rubber-stamps a treatment, companies can market it legally within Montana.

The move positions Montana as an experimental medical hub, allowing residents early access to therapies not yet cleared by federal regulators. Supporters argue this creates options for patients with limited alternatives, particularly those with terminal or rare conditions. The state essentially created its own regulatory authority to compete with the FDA's slower approval timeline.

However, the approach carries serious risks. Preliminary testing on small cohorts provides minimal safety and efficacy data. Drugs approved through this process lack the rigorous multi-phase trials required by federal regulators, where thousands of patients receive treatment and adverse effects emerge. The state board's qualifications and expertise remain unclear, raising questions about whether reviewers possess adequate medical or scientific training to evaluate drug safety claims.

Patient protection advocates worry this creates an unregulated market for unproven treatments. Companies could exploit vulnerable populations desperate for hope. Weak state oversight invites fraud and ineffective remedies while limiting liability protections consumers normally receive through FDA-approved channels.

The Montana experiment reflects broader tension between access and safety. Federal approval processes prioritize rigorous evidence but move slowly. State-level alternatives promise faster innovation but risk enabling harmful or worthless treatments. The FDA likely views this as territorial encroachment on federal drug regulation authority, though legal challenges remain uncertain.

Other states may watch Montana's approach closely. If the model succeeds without major safety incidents, copycat legislation could follow. If it produces patient harm, it may trigger federal intervention or